24 Chapter 2 also focused on blood glucose changes in people with known DM status, not those with a normal blood glucose level before commencing TB treatment. Patients with known blood glucose anomalies will receive special care during TB treatment, but those presumed to have normal blood glucose may have poor treatment outcomes if abnormal changes in blood glucose were missed during treatment. Therefore, the objective of this scoping review was to identify and compile the available evidence on possible abnormalities in blood glucose in previously normoglycaemic patients during and after TB treatment, using studies published from 1980 to 2021. Methods This review was developed using the JBI reviewer's manual and the methodology is based on the framework developed by Arksey and O’Malley [23, 24]. Scoping review questions The following questions were used as a guide to fully describe the topic of this scoping review and the articles included in the review: 1. What methodology has been employed in describing the abnormal blood glucose arising from TB treatment? 2. What approaches have been identified as appropriate for measuring blood glucose during TB treatment? 3. What is the TB treatment outcome for patients who develop abnormal blood glucose while on TB treatment? 4. What factors determine the occurrence of abnormal blood glucose during TB treatment? 5. What is the frequency of abnormal glucose tolerance or DM in patients receiving TB treatment? Information sources and search strategy A search was done for studies describing TB treatment’s effect on patients’ glucose levels from 1 January 1980 to 30 June 2021. This period was chosen to accommodate the increase in HIV infections that led to an increase in the number of new TB cases [25, 26]. We searched the PubMed, Web of Science, CINAHL and Embase databases. A three-step approach was used to identify articles for inclusion in the review [23]. The first step was a preliminary search that involved identifying index terms and MeSH
RkJQdWJsaXNoZXIy MTk4NDMw